Aspirin for primary prevention of cardiovascular events: Meta-analysis of randomized controlled trials and subgroup analysis by sex and diabetes status

PLoS ONE

Volumn 9, Issue 10, 2014, Pages

  Xie, Manling ^a   Shan, Zhilei ^a   Zhang, Yan ^a   Chen, Sijing ^a   Yang, Wei ^a   Bao, Wei ^a   Rong, Ying ^a   Yu, Xuefeng ^b   Hu, Frank B ^c   Liu, Liegang ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; PLACEBO;

ARTICLE; BLEEDING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; LOW DRUG DOSE; MALE; META ANALYSIS; MORTALITY; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; RISK REDUCTION; SYSTEMATIC REVIEW; CARDIOVASCULAR DISEASES; PATHOLOGY; PUBLISHING; REGRESSION ANALYSIS; TREATMENT OUTCOME;

ASPIRIN; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; FEMALE; HUMANS; MALE; PLACEBOS; PUBLICATION BIAS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGRESSION ANALYSIS; TREATMENT OUTCOME;

EID: 84910018779     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0090286     Document Type: Article

References (79)

1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, et al. (2013) Heart disease and stroke statistics-2013 update: a report from the American Heart Association. Circulation 127: e6-e245.
2. (2009) Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 150: 396-404.
3. Wolff T, Miller T, Ko S (2009) Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 150: 405-410.
4. De Berardis G, Lucisano G, D'Ettorre A, Pellegrini F, Lepore V, et al. (2012) Association of aspirin use with major bleeding in patients with and without diabetes. JAMA 307: 2286-2294.
5. Kappagoda T, Amsterdam E (2012) Aspirin for primary prevention of myocardial infarction: what is the evidence? J Cardiopulm Rehabil Prev 32: 1-8.
6. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, et al. (2006) Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 295: 306-313.
7. Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, et al. (2009) Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373: 1849-1860.
8. Berger JS, Lala A, Krantz MJ, Baker GS, Hiatt WR (2011) Aspirin for the prevention of cardiovascular events in patients without clinical cardiovascular disease: a meta-analysis of randomized trials. Am Heart J 162: 115-124 e112.
9. Rothwell PM, Price JF, Fowkes FG, Zanchetti A, Roncaglioni MC, et al. (2012) Short-term effects of daily aspirin on cancer incidence, mortality, and nonvascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 379: 1602-1612.
10. Ghahramani P, Jackson PR, Wallis EJ, Ramsay LE (2001) Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart 85: 265-271.
11. Seshasai SR, Wijesuriya S, Sivakumaran R, Nethercott S, Erqou S, et al. (2012) Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. Arch Intern Med 172: 209-216.
12. Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, et al. (2007) Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation 115: 114-126.
13. (2008) Type 2 Diabetes: National Clinical Guideline for Management in Primary and Secondary Care (Update). London: Royal College of Physicians of London.
14. Ryden L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, et al. (2007) Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 28: 88-136.
15. De Berardis G, Sacco M, Strippoli GFM, Pellegrini F, Graziano G, et al. (2009) Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. Bmj 339: b4531-b4531.
16. Calvin AD, Aggarwal NR, Murad MH, Shi Q, Elamin MB, et al. (2009) Aspirin for the primary prevention of cardiovascular events: a systematic review and meta-analysis comparing patients with and without diabetes. Diabetes Care 32: 2300-2306.
17. Younis N, Williams S, Ammori B, Soran H (2010) Role of aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: a meta-analysis. Expert Opin Pharmacother 11: 1459-1466.
18. Zhang C, Sun A, Zhang P, Wu C, Zhang S, et al. (2010) Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis. Diabetes Res Clin Pract 87: 211-218.
19. Pignone M, Alberts MJ, Colwell JA, Cushman M, Inzucchi SE, et al. (2010) Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of the American College of Cardiology Foundation. Diabetes Care 33: 1395-1402.
20. Stavrakis S, Stoner JA, Azar M, Wayangankar S, Thadani U (2011) Low-dose aspirin for primary prevention of cardiovascular events in patients with diabetes: a meta-analysis. Am J Med Sci 341: 1-9.
21. Butalia S, Leung AA, Ghali WA, Rabi DM (2011) Aspirin effect on the incidence of major adverse cardiovascular events in patients with diabetes mellitus: a systematic review and meta-analysis. Cardiovasc Diabetol 10: 25.
22. Simpson SH, Gamble JM, Mereu L, Chambers T (2011) Effect of aspirin dose on mortality and cardiovascular events in people with diabetes: a meta-analysis. J Gen Intern Med 26: 1336-1344.
23. Schnell O, Erbach M, Hummel M (2012) Primary and secondary prevention of cardiovascular disease in diabetes with aspirin. Diab Vasc Dis Res 9: 245-255.
24. Altman DG, Bland JM (2003) Interaction revisited: the difference between two estimates. BMJ 326: 219.
25. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339: b2535.
26. Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, et al. (2011) Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 123: 2736-2747.
27. Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen LS, et al. (1987) Thrombolysis in Myocardial Infarction (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 76: 142-154.
28. The GUSTO investigators (1993) An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 329: 673-682.
29. Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, et al. (2011) The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 343: d5928.
30. Higgins JP, Thompson SG, Deeks JJ, Altman DG (2003) Measuring inconsistency in meta-analyses. BMJ 327: 557-560.
31. Higgins JP (2008) Commentary: Heterogeneity in meta-analysis should be expected and appropriately quantified. Int J Epidemiol 37: 1158-1160.
32. Lau J, Ioannidis JP, Schmid CH (1997) Quantitative synthesis in systematic reviews. Ann Intern Med 127: 820-826.
33. Laupacis A, Sackett DL, Roberts RS (1988) An assessment of clinically useful measures of the consequences of treatment. N Engl J Med 318: 1728-1733.
34. van Houwelingen HC, Arends LR, Stijnen T (2002) Advanced methods in meta-analysis: multivariate approach and meta-regression. Stat Med 21: 589-624.
35. Peto R, Gray R, Collins R, Wheatley K, Hennekens C, et al. (1988) Randomised trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed) 296: 313-316.
36. Steering Committee of the Physicians' Health Study Research Group (1989) Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 321: 129-135.
37. (1992) Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. ETDRS Investigators. JAMA 268: 1292-1300.
38. Cote R, Battista RN, Abrahamowicz M, Langlois Y, Bourque F, et al. (1995) Lack of effect of aspirin in asymptomatic patients with carotid bruits and substantial carotid narrowing. The Asymptomatic Cervical Bruit Study Group. Ann Intern Med 123: 649-655.
39. (1998) Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework. Lancet 351: 233-241.
40. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, et al. (1998) Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. The Lancet 351: 1755-1762.
41. de Gaetano G (2001) Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet 357: 89-95.
42. Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, et al. (2004) Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 350: 114-124.
43. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, et al. (2005) A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 352: 1293-1304.
44. Catalano M, Born G, Peto R (2007) Prevention of serious vascular events by aspirin amongst patients with peripheral arterial disease: randomized, double-blind trial. J Intern Med 261: 276-284.
45. Erkan D, Harrison MJ, Levy R, Peterson M, Petri M, et al. (2007) Aspirin for primary thrombosis prevention in the antiphospholipid syndrome: a randomized, double-blind, placebo-controlled trial in asymptomatic antiphospholipid antibody-positive individuals. Arthritis Rheum 56: 2382-2391.
46. Belch J, MacCuish A, Campbell I, Cobbe S, Taylor R, et al. (2008) The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 337: a1840.
47. Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, et al. (2008) Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 300: 2134-2141.
48. Fowkes FG, Price JF, Stewart MC, Butcher I, Leng GC, et al. (2010) Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA 303: 841-848.
49. Algra A, Greving JP (2009) Aspirin in primary prevention: sex and baseline risk matter. Lancet 373: 1821-1822.
50. Hernandez-Diaz S, Rodriguez LA (2002) Incidence of serious upper gastrointestinal bleeding/perforation in the general population: review of epidemiologic studies. J Clin Epidemiol 55: 157-163.
51. Pearson TA, Blair SN, Daniels SR, Eckel RH, Fair JM, et al. (2002) AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 106: 388-391.
52. Hernandez-Diaz S, Garcia Rodriguez LA (2006) Cardioprotective aspirin users and their excess risk of upper gastrointestinal complications. BMC Med 4: 22.
53. Reid CM, Storey E, Wong TY, Woods R, Tonkin A, et al. (2012) Aspirin for the prevention of cognitive decline in the elderly: rationale and design of a neurovascular imaging study (ENVIS-ion). BMC Neurol 12: 3.
54. Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, et al. (2010) Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 375: 2215-2222.
55. Alzahrani SH, Ajjan RA (2010) Coagulation and fibrinolysis in diabetes. Diab Vasc Dis Res 7: 260-273.
56. Undas A, Brummel-Ziedins KE, Mann KG (2007) Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions. Blood 109: 2285-2292.
57. Hamberg M, Svensson J, Samuelsson B (1975) Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci U S A 72: 2994-2998.
58. FitzGerald GA (1991) Mechanisms of platelet activation: thromboxane A2 as an amplifying signal for other agonists. Am J Cardiol 68: 11B-15B.
59. Roth GJ, Stanford N, Majerus PW (1975) Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci U S A 72: 3073-3076.
60. Tschoepe D (1995) The activated megakaryocyte-platelet-system in vascular disease: focus on diabetes. Semin Thromb Hemost 21: 152-160.
61. Watala C, Golanski J, Pluta J, Boncler M, Rozalski M, et al. (2004) Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin)-its relation to metabolic control. Thromb Res 113: 101-113.
62. Mylotte D, Kavanagh GF, Peace AJ, Tedesco AF, Carmody D, et al. (2012) Platelet reactivity in type 2 diabetes mellitus: a comparative analysis with survivors of myocardial infarction and the role of glycaemic control. Platelets 23: 439-446.
63. Grove EL, Hvas AM, Mortensen SB, Larsen SB, Kristensen SD (2011) Effect of platelet turnover on whole blood platelet aggregation in patients with coronary artery disease. J Thromb Haemost 9: 185-191.
64. Perneby C, Wallen NH, Rooney C, Fitzgerald D, Hjemdahl P (2006) Dose- and time-dependent antiplatelet effects of aspirin. Thromb Haemost 95: 652-658.
65. Spectre G, Arnetz L, Ostenson CG, Brismar K, Li N, et al. (2011) Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro- or macrovascular complications. Thromb Haemost 106: 491-499.
66. Capodanno D, Patel A, Dharmashankar K, Ferreiro JL, Ueno M, et al. (2011) Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease. Circ Cardiovasc Interv 4: 180-187.
67. Vivas D, Bernardo E, Garcia-Rubira JC, Azcona L, Nunez-Gil I, et al. (2011) Can resistance to aspirin be reversed after an additional dose? J Thromb Thrombolysis 32: 356-361.
68. Mortensen SB, Larsen SB, Grove EL, Kristensen SD, Hvas AM (2010) Reduced platelet response to aspirin in patients with coronary artery disease and type 2 diabetes mellitus. Thromb Res 126: e318-322.
69. De Berardis G, Sacco M, Evangelista V, Filippi A, Giorda CB, et al. (2007) Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins. Trials 8: 21.
70. Patrignani P, Filabozzi P, Patrono C (1982) Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 69: 1366-1372.
71. Patrono C, Ciabattoni G, Patrignani P, Pugliese F, Filabozzi P, et al. (1985) Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation 72: 1177-1184.
72. Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C (2005) Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 353: 2373-2383.
73. Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR (2008) Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 336: 195-198.
74. Raichand S, Moore D, Riley RD, Lordkipanidze M, Dretzke J, et al. (2013) Protocol for a systematic review of the diagnostic and prognostic utility of tests currently available for the detection of aspirin resistance in patients with established cardiovascular or cerebrovascular disease. Syst Rev 2: 16.
75. Milicic D, Skoric B (2011) [Aspirin resistance]. Lijec Vjesn 133: 337-342.
76. Patrono C (2003) Aspirin resistance: definition, mechanisms and clinical readouts. J Thromb Haemost 1: 1710-1713.
77. Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G (2004) Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126: 234S-264S.
78. Derry S, Loke YK (2000) Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ 321: 1183-1187.
79. Kelly JP, Kaufman DW, Jurgelon JM, Sheehan J, Koff RS, et al. (1996) Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 348: 1413-1416.